Although the clinical utility of glycohemoglobin (HbA1#{224} as an indicator of blood glucose control is generally accepted, the use of cation-exchange liquid chromatography for its quantification is controversial, given numerous studiesthat show no correlation between HbA1Cand other indicatorsof blood glucose control in uremic subjects. We report a specific cation-exchange liquid-chromatographic method that measures simultaneously HbAIa, HbAlb, HbA1C,HbF, HbA0, HbC, and HbS quickly and reproducibly. Carbamylation or acetylation is indicated by extra peaks. Carbamylated hemoglobin increased the resultfor HbA1Cby as much as 1% above the nonuremicvalue. The method is a fast (-15 mm per sample), easy to perform, reproducible, and sensitive screening method for abnormal hemoglobins. Within-assay CVs were <0.7% in all cases and between-assay CVs were <1.4%.
Although the clinical utility of glycohemoglobin (HbA1#{224} as an indicator of blood glucose control is generally accepted, the use of cation-exchange liquid chromatography for its quantification is controversial, given numerous studiesthat show no correlation between HbA1Cand other indicatorsof blood glucose control in uremic subjects. We report a specific cation-exchange liquid-chromatographic method that measures simultaneously HbAIa, HbAlb, HbA1C,HbF, HbA0, HbC, and HbS quickly and reproducibly. Carbamylation or acetylation is indicated by extra peaks. Carbamylated hemoglobin increased the resultfor HbA1Cby as much as 1% above the nonuremicvalue. The method is a fast (-15 mm per sample), easy to perform, reproducible, and sensitive screening method for abnormal hemoglobins. Within-assay CVs were <0.7% in all cases and between-assay CVs were <1.4%. Received January 25, 1993; accepted July 20, 1993.
globin. Until now, carbamylated hemoglobin has been coeluted with gHb in cation-exchange chromatography (5). We describe an optimized HPLC procedure in which uremia is indicated by the presence of an extra peak. For method comparison we used affinity chromatography.
Materials and Methods

Apparatus
Our chromatographic system consisted of a Waters (Milford, MA) 600 E multisolvent delivery system and a Waters 700 Satellite Wisp autosampler.
A Waters 994 programmable diode-array detector was used with a Waters 5200 printer plotter. The chromatograms were recorded with the Waters Maxima Baseline system. The column used was a 5 x 50 mm 8-nm particle size ionexchange Protein-Pak SP-8HR column (Waters).
Reagents
Triton X-100 was from Boom (Meppel, The Netherlands). Boric acid (Analar grade) was from BDH (Poole, UK). All other reagents (analytical grade) were from Merck (Darmst.adt, Germany). We used glass-distilled demineralized water. Hemolysis solution. Per liter, 120 mmol of boric acid and 1 mL of Triton X-l00. The solution was titrated to pH 5.9 with 6 mol/L NaOH.
BufferA. Per liter, 0.01 mol of malonic acid and 0.2 g of sodium aside. The buffer was titrated to pH 5.70 (±0.02) with 6 mol/L NaOH.
Buffer B. Per liter, 0.01 mol of malomc acid, 300 mmol of LiCl, and 1.0 g of sodium aside. The buffer was titrated to pH 5.70 (±0.02) with 6 mol/L NaOH.
Other reagents. Pump-head cleaning solution, methanol in water (25/75, by vol). Glass-distilled water with sodium azide, 0.2 g/L. NaOH, 0.1 mol/L. Acetic acid, 300 milL. Lid, 1 mmolJL. Methanol, 250 milL. All buffers and solutions were filtered over 0.45-sm (pore size) filter units (Millipore, Milford, MA).
Samples
Blood was collected in 3.8-mL EDTA.containing Venoject Tubes (Terumo Europe NV, Leuven, Belgium). We followed the procedures of the revised Helsinki Declaration of 1983.
Urea and triglyceride concentrations were determined with a Hitachi 737 analyzer (Boehringer Mannheim, Mannheim, Germany). To assess sample stability, we stored aliquots of whole-blood samples for 2, 5, and 9 days at room temperature and at 4#{176}C.
Procedures
Sample preparation and hemolysis. We pipetted 25 L of EDTA-treated blood into 2 mL of isotonic saline (NaCl 9 giL) with a Hamilton (Bonaduz, Switzerland) Digital diluter. The cells were centrifuged at 1500 x g for 10 mm, and the aupernates were discarded. The cell pellets were dissolved in 1 mL of hemolysis solution. After vortex-minng these samples, we centrifuged the cell debris at 1500 x g for 10 mm. The resulting clear supernate was pipetted into vials before analysis. Chromatographic conditions. The sample volume injected was 5 L. The pump speed was 1.0 mLlmin, the detection wavelength was 417 nm with a baseline correction at 465 nm, and the sensitivity was 0.500 AN. Each analysis included two human blood-based quality-control specimens before and after the patients' sample series. The column was equilibrated with 82% buffer A and 18% buffer B for 30 mm before sample application. To elute the hemoglobins, we increased the volume proportion of buffer B in the mobile phase to 40% by 6 mm after injection and to 100% by 7.5 mm, decreasing this back to 18% by 10 mm. We reequilibrated the column with 18% buffer B for at least 5 mm before applying the next sample. After the assay, we washed the column with 45 mL of distified water and injected 300 L of 1.0 mol/L LiCl.
We regenerated the column each week by washing it sequentially with 5 mL of distilled water, 5 mL of 0.1 mol/L NaOH, 5 mL of distified water, 5 mL of 300 milL acetic acid, 5 mL of distilled water, and 5 mL of 1 mol/L Lid.
Assay Optimization
We investigated the optimal sample preparation before analysis. To determine the optimal hemolysis conditions, we added Triton X-100, distilled water, or boric acid at different temperatures.
The elution buffers we tested were malonic acid and phosphate buffers at various pH values. The optimal wavelength for HbAIC and baseline correction was evaluated. Sample volume was investigated for linearity with assay results. We investigated the influence of urea, salicylic acid, and high triglyceride concentrations on the measurement of HbA1. We also compared our HPLC method with an affinity chromatographic method (Glycotest II; Pierce, Rockford, IL) and quantified glycohemoglobin according to the manufacturers' instructions.
Statistical Analysis
For statistical comparisons between the fresh samples and the samples stored at different temperatures we used paired Student's t-test. We also evaluated the different hemolysis conditions data with the paired Student's t-test. Correlation studies were done by linear regression analysis according to Deming (6) .
Results
Sample pretreatment.
We investigated the influence of washing the samples with isotonic saline. In vitro carbamylation.
To estimate the influence of urea on the results, we incubated with urea (final concentration 238 mmoi/L) whole-blood samples of diabetic patients without uremia for 24 h at 37#{176}C. The mean (± SD) HbA1 content of samples without urea addition was 7.38% (1.03%), with a carbamylated Hb content of 3.19% (0.16%). After addition of urea, the mean HbA1 was 8.09% (1.06%), with a carbamylated Hb of 3.76% (0.16%). This difference was significant (P <0.01). The results were not changed when the whole-blood samples were washed before incubation with the various urea concentrations 50 mmolfL (results not shown). The influence of salicylic acid was investigated according to Nathan et al. (7), incubating whole-blood samples of nondiabetic patients without uremia with 4 mmol/L salicylic acid for 7 h at 37#{176}C (Figure  1 ). 
Carbamylated
Hb was added to hemolysates from Accuracy. Our HPLC method was compared with the affinity chromatographic method. Orthogonal regression analysis was done according to Deming (6) . As shown in Figure 3 , the correlation between the two methods was excellent, although there is a substantial absolute difference.
Precision. We investigated the within-day and between-day precision of the assay. The results are shown in Table 1 .
Linearity. The injection volume of the sample was 5 L; this corresponds to 20 pg of protein and was enough for obtaining a good linearity and an optimal detector response. The capacity of the column is 40mg of protein.
The response of the detector was linear from 1 to 100 L of injected sample volume.
Reference interval. The reference interval was determined by measuring the HbA1 fraction in the blood from healthy laboratory personnel and nurses. The mean (±SD) of the 189 participants was 4.89% (0.40%). The reference interval (mean ± 2 SD) was thus 4.1-5.7%. 
Discussion
The purpose of the present study was to develop a HPLC method that would be easy to perform with good reproducibility and was also suitable for screening for modified hemoglobins.
First we set up a simple procedure for sample pretreatment.
Before hydrolysis the erythrocytes were washed with isotonic saline. This is a prerequisite for a clean chromatogram, especially in 
(8).
The peaks deteriorated after >2500 injections; after treatment with trypsin and regeneration, the column could be used for another 1500 samples.
The effect of incubating the samples at 37#{176}C for several hours was evaluated.
After incubation we hemolyzed the cells with various hemolyzing solutions. Glassdistilled water with various concentrations of Triton X-100 and with or without boric acid at different concentrations was used. We obtained excellent results with washed cells that were directly hemolyzed with 120 mmol of boric acid and 1 mL of Triton X-100 per liter; preincubation at 37#{176}C was no longer necessary. The mean values of samples incubated without boric acid for 2 h at 37#{176}C were nearly identical with those of samples not incubated with boric acid (mean difference 0.20%). This could be due to the fact that the labile fraction is bound by boric acid.
Evaluation of conditions for sample storage showed that the results after storage at 22#{176}C for 5 days were nearly identical to those for fresh samples. of HbA1, yielding a higher result (5). In the method we developed, uremia is indicated by an increase of an extra peak in the chromatogram. Under normal conditions this peak was always <4% of HbA.
Greater percentages
were associated with patients with uremia. The percentage of HbA1 was increased by as much as 1% in cases of severe uremia. Acetylation, as evaluated with salicylic acid, was indicated by an increase of another extra peak. A high triglycerides concentration had no influence on the result because of the wash step before hemolysis.
There was excellent correlation between our HPLC method and affinity chromatography.
The difference between the two methods is substantially due to the fact that affinity chromatography measures the cis-diol groups of gHb, whereas the HPLC method measures HbA1C.
In summary,
we have developed an easy, fast HPLC method for measuring HbA1C. Because
HbF, HbS, and HbC are separated in the same run, the method is also a reliable way to screen for abnormal hemoglobins. There is no interference of triglycerides, and uremic samples are indicated in the chromatogram. Unfortunately, because of the wide variety of assay methods for HbA1C, the data generated in one laboratory are difficult to relate to those generated by another. The need for standardization is obvious (21); nonetheless, it would be difficult to prepare a combination of purified gHbs for use with all assays of gHb.
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